BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare Oncology Disease Analysis: NHL: Follicular Lymphoma

July 05, 2021

Despite being essentially incurable, follicular lymphoma progresses very slowly, meaning that five-year survival rates are relatively high. Treatments are largely intended to drive the disease into remission until recurrence, at which point another round of therapy will be required. 

Since its approval in 1997, most recommended regimens, particularly in the first-line setting, combine the CD20 antagonist Rituxan with chemotherapy. Rituximab biosimilars are now widely available. 

Another CD20 antibody, Gazyva, has also found modest success in early lines of therapy. 

Most pipeline development concerns therapies for heavily pretreated disease. Notable innovations in this space include PI3K inhibitors, BTK inhibitors, bispecific T-cell engagers (BiTEs), and anti-CD19 CAR-T therapies. 

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Indolent Non-Hodgkin's Lymphoma (Including Follicular Lymphoma) - NHL
Back to the top Back to the top